Akari Therapeutics, Plc (AKTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Akari Therapeutics, Plc (AKTX) closed at USD 7.28 on 2026-10-14, a change of -76.4 % over the past year, with a market capitalization of USD 20.2M.

Akari Therapeutics, Plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Akari Therapeutics, Plc key figures

Previous close

USD 7.28 (2026-10-14)

1-year change

-76.4 %

Market cap

USD 20.2M

Enterprise value

USD 10.21M

P/E ratio (trailing)

n/a

P/E ratio (forward)

-1.02

EPS (trailing)

0.00

EPS (forward)

-8.65

PEG ratio

n/a

Price to book

0.83

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.18

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Akari Therapeutics, Plc and compare it with other stocks.